A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab

References

• Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008;358:2606-17
   PubMed Web of Science ®Google Scholar
• Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844-51
   PubMed Web of Science ®Google Scholar
• Gehrs KM, Anderson DH, Johnson LV, et al. Age-related macular degeneration – emerging pathogenetic and therapeutic concepts. Ann Med 2006;38:450-71
   PubMed Web of Science ®Google Scholar
• Emerson MV, Lauer AK. Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol 2008;2:377-88
   PubMedGoogle Scholar
• Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7
   PubMed Web of Science ®Google Scholar
• Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997;81:154-62
   PubMed Web of Science ®Google Scholar
• Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002;120:1644-50
   PubMed Web of Science ®Google Scholar
• Kvanta A, Algvere PV, Berglin L, et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929-34
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Adamis AP, Cunningham ET Jr., et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113:1508 e1-25
   PubMed Web of Science ®Google Scholar
• D'Amico DJ, Masonson HN, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113:992-1001 e6
   PubMed Web of Science ®Google Scholar
• Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999;293:865-81
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44
   PubMed Web of Science ®Google Scholar
• Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65 e5
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 2006;19:361-72
   PubMedGoogle Scholar
• Bashshur ZF, Schakal A, Hamam RN, et al. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 2007;125:1357-61
   PubMed Web of Science ®Google Scholar
• Hahn R, Sacu S, Michels S, et al. [Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration]. Ophthalmologe 2007;104:588-93
   PubMed Web of Science ®Google Scholar
• Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114:1179-85
   PubMed Web of Science ®Google Scholar
• Potter MJ, Claudio CC, Szabo SM. A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study. Br J Ophthalmol 2010;94:174-9
   PubMed Web of Science ®Google Scholar
• Sacu S, Michels S, Prager F, et al. Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results. Eye (Lond) 2009;23:2223-7
   PubMed Web of Science ®Google Scholar
• Subramanian ML, Ness S, Abedi G, et al. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. Am J Ophthalmol 2009;148:875-82 e1
   PubMed Web of Science ®Google Scholar
• Tufail A, Patel PJ, Egan C, et al. Avastin (Bevacizumab) for choroidal neovascularisation in age-related macular degeneration (ABC) trial. BMJ 2010;340:c2459
   PubMed Web of Science ®Google Scholar
• Weigert G, Michels S, Sacu S, et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 2008;92:356-60
   PubMed Web of Science ®Google Scholar
• Genentech. Avastin prescribing information. 2010
   Google Scholar
• Kahook MY, Liu L, Ruzycki P, et al. High-molecular-weight aggregates in repackaged bevacizumab. Retina 2010;30:887-92
   PubMed Web of Science ®Google Scholar
• Novartis. Lucentis prescribing information. 2006
   Google Scholar
• USP 28/NF 23, Chapter <788> “Particulate Matter in Injections” United States Pharmacopeial Convention, Inc Rockville, MD, 2005
   Google Scholar
• USP 28/NF 23 Chapter <789> “Particulate Matter in Ophthalmic Solutions”. United States Pharmacopeial Convention, Inc Rockville, MD, 2005
   Google Scholar
• Sharma S. The comparative safety of intravitreal bevacizumab versus ranibizumab for retinal disease. 28th Annual Meeting of the American Society of Retina Specialists; 2010 August 28–September 1, 2010; Vancouver, BC, Canada, 2010
   Google Scholar
• Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age-related macular degeneration. Lancet 2007;370:204-6
   PubMed Web of Science ®Google Scholar
• Liew G, Mitchell P. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2007;356:747-8; author reply 9-50
   PubMed Web of Science ®Google Scholar
• Oxford Centre for Evidence-based Medicine -- Levels of Evidence (March 2009). Available at http://www.cebm.net/index.aspx?o=1025. Accessed October 2010
   Google Scholar
• Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010;94:2-13
   PubMed Web of Science ®Google Scholar
• Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124:1532-42
   PubMed Web of Science ®Google Scholar
• Bressler NM, Chang TS, Fine JT, et al. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Arch Ophthalmol 2009;127:13-21
   PubMed Web of Science ®Google Scholar
• Chang TS, Bressler NM, Fine JT, et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 2007;125:1460-9
   PubMed Web of Science ®Google Scholar
• Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-48
   PubMed Web of Science ®Google Scholar
• Antoszyk AN, Tuomi L, Chung CY, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008;145:862-74
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Heier JS, Hantsbarger G, et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006;113:623-32e1
   PubMed Web of Science ®Google Scholar
• Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113:633-42e4
   PubMed Web of Science ®Google Scholar
• Boyer DS, Heier JS, Brown DM, et al. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116:1731-9
   PubMed Web of Science ®Google Scholar
• Tano Y, Ohji M. EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Acta Ophthalmol 2010;88:309-16
   PubMed Web of Science ®Google Scholar
• Subramanian ML, Abedi G, Ness S, et al. Bevacizumab vs ranibizumab: one year outcomes of a head-to-head, prospective, double-masked, randomized clinical trial. Presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), May 2, 2010
   Google Scholar
• Schmucker C, Antes G, Lelgemann M, et al. Treatment of age-related macular degeneration: evidence report. German Cochrane Center, 25 September, 2009
   Google Scholar
• Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-9
   PubMed Web of Science ®Google Scholar
• Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007;41:614-25
   PubMed Web of Science ®Google Scholar
• Schmucker C, Antes G, Lelgemann M. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2010;248:451-2
   PubMed Web of Science ®Google Scholar
• McGimpsey SJ, Gillies MC. Treatment of macular degeneration – controversy and hope. Br J Ophthalmol 2008;92:436-7
   PubMed Web of Science ®Google Scholar
• Roth DB, King A, Weiss M, et al. Systemic adverse events after bevacizumab. Ophthalmology 2009;116:1226 e1
   PubMed Web of Science ®Google Scholar
• Dafer RM, Schneck M, Friberg TR, et al. Intravitreal ranibizumab and bevacizumab: a review of risk. Semin Ophthalmol 2007;22:201-4
   PubMedGoogle Scholar
• Schmidt-Erfurth U. Clinical safety of ranibizumab in age-related macular degeneration. Expert Opin Drug Saf 2010;9:149-65
   PubMed Web of Science ®Google Scholar
• Genentech. Genentech: Reports of intraocular inflammatory reactions after intravitreal injection with AVASTIN. Available at http://www.fiercebiotech.com/press-releases/genentech-reports-intraocular-inflammatory-reactions-after-intravitreal-injection-ava. Accessed July 2010
   Google Scholar
• HealthCanada. Reports of eye inflammation, endophthalmitis, and toxic anterior segment syndrome (TASS) following off-label intravitreal use of AVASTIN® (bevacizumab). Available at http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2008/avastin_4_hpc-cps-eng.php. Accessed July 2010
   Google Scholar
• Holland S. Update on bevacizumab (Avastin)-associated post-operative inflammation (TASS, Sterile Endophthalmitis). Canadian Ophthalmological Society newsletter (http://wwweyesiteca/Perspectives/September2009/September_ephp) 2009
   Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
   PubMed Web of Science ®Google Scholar
• Tan JS, Wang JJ, Liew G, et al. Age-related macular degeneration and mortality from cardiovascular disease or stroke. Br J Ophthalmol 2008;92:509-12
   PubMed Web of Science ®Google Scholar
• Alexander SL, Linde-Zwirble WT, Werther W, et al. Annual rates of arterial thromboembolic events in Medicare neovascular age-related macular degeneration patients. Ophthalmology 2007;114:2174-8
   PubMed Web of Science ®Google Scholar
• Tan JS, Mitchell P, Smith W, et al. Cardiovascular risk factors and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 2007;114:1143-50
   PubMed Web of Science ®Google Scholar
• Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-70
   PubMed Web of Science ®Google Scholar
• Curtis LH, Hammill BG, Schulman KA, et al. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010;128:1273-9
   PubMed Web of Science ®Google Scholar
• Ross JS, Madigan D, Hill KP, et al. Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Arch Intern Med 2009;169:1976-85
   PubMed Web of Science ®Google Scholar
• Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695 e1-15
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-9
   PubMed Web of Science ®Google Scholar
• Dib E, Maia M, Longo-Maugeri IM, et al. Subretinal bevacizumab detection after intravitreous injection in rabbits. Invest Ophthalmol Vis Sci 2008;49:1097-100
   PubMed Web of Science ®Google Scholar
• Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009;50:4807-13
   PubMed Web of Science ®Google Scholar